Eagle Pharmaceuticals Accounts Payable

Eagle Pharmaceuticals (EGRX) currently reports a accounts payable of $16M as of June 2023. That compares with $20M in the prior-year period — down 20.7% year over year. Use the charts on this page to explore Eagle Pharmaceuticals's accounts payable history and peer comparisons.

Eagle Pharmaceuticals's accounts payable decreased from $20M to $16M — a 20.7% year-over-year decrease (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Eagle Pharmaceuticals reported $16M in accounts payable as of June 2023. That compares with $20M in the prior-year period — down 20.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $16M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Eagle Pharmaceuticals, and consider following EGRX for alerts when major investors trade the stock.

Eagle Pharmaceuticals is classified in the Healthcare sector. On accounts payable, it currently shows $16M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EGRX with unrelated industries.